Monitoring Progression of Ductal Carcinoma In Situ Using Photoacoustics and Contrast-Enhanced Ultrasound.
Journal
Translational oncology
ISSN: 1936-5233
Titre abrégé: Transl Oncol
Pays: United States
ID NLM: 101472619
Informations de publication
Date de publication:
Jul 2019
Jul 2019
Historique:
received:
24
04
2019
accepted:
28
04
2019
pubmed:
24
5
2019
medline:
24
5
2019
entrez:
24
5
2019
Statut:
ppublish
Résumé
Breast cancer is the leading form of cancer in women, accounting for approximately 41,400 deaths in 2018. While a variety of risk factors have been identified, physical exercise has been linked to reducing both the risk and aggressiveness of breast cancer. Within breast cancer, ductal carcinoma in situ (DCIS) is a common finding. However, less than 25% of DCIS tumors actually progress into invasive breast cancer, resulting in overtreatment. This overtreatment is due to a lack of predictive precursors to assess aggressiveness and development of DCIS. We hypothesize that tissue oxygenation and perfusion measured by photoacoustic and contrast-enhanced ultrasound imaging, respectively, can predict DCIS aggressiveness. To test this, 20 FVB/NJ and 20 SV40Tag mice that genetically develop DCIS-like breast cancers were divided evenly into exercise and control groups and imaged over the course of 6 weeks. Tissue oxygenation was a predictive precursor to invasive breast cancer for FVB/NJ mice (P = 0.015) in the early stages of tumor development. Meanwhile, perfusion results were inconclusive (P > 0.2) as a marker for disease progression. Moreover, voluntary physical exercise resulted in lower weekly tumor growth and significantly improved median survival (P = 0.014).
Identifiants
pubmed: 31121489
pii: S1936-5233(19)30187-1
doi: 10.1016/j.tranon.2019.04.018
pmc: PMC6529783
pii:
doi:
Types de publication
Journal Article
Langues
eng
Pagination
973-980Subventions
Organisme : NIH HHS
ID : S10 OD010408
Pays : United States
Informations de copyright
Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.
Références
J Clin Oncol. 2001 Aug 1;19(15):3524-31
pubmed: 11481359
Nat Rev Cancer. 2002 Jan;2(1):38-47
pubmed: 11902584
Oncologist. 2004;9 Suppl 5:4-9
pubmed: 15591417
CA Cancer J Clin. 2007 Mar-Apr;57(2):75-89
pubmed: 17392385
Eur J Radiol. 2010 Feb;73(2):288-93
pubmed: 19559551
Ultrasound Med Biol. 2009 Oct;35(10):1587-95
pubmed: 19682788
J Control Release. 2010 Apr 2;143(1):38-44
pubmed: 20060024
J Am Coll Radiol. 2010 Jan;7(1):18-27
pubmed: 20129267
Eur J Nucl Med Mol Imaging. 2010 Aug;37 Suppl 1:S138-46
pubmed: 20461376
Radiology. 2011 Sep;260(3):616-20
pubmed: 21846757
AJR Am J Roentgenol. 2012 Jan;198(1):233-9
pubmed: 22194502
Clin Hemorheol Microcirc. 2011;49(1-4):137-49
pubmed: 22214685
Front Immunol. 2012 Feb 23;3:21
pubmed: 22566905
Interface Focus. 2011 Aug 6;1(4):602-31
pubmed: 22866233
J Phys Act Health. 2014 Feb;11(2):445-54
pubmed: 23416687
Wien Klin Wochenschr. 2013 Jun;125(11-12):297-301
pubmed: 23653151
IEEE Trans Ultrason Ferroelectr Freq Control. 2013 May;60(5):888-97
pubmed: 23661123
J Breast Cancer. 2013 Jun;16(2):208-13
pubmed: 23843855
Ultrason Imaging. 2015 Jan;37(1):42-52
pubmed: 24652195
Crit Rev Eukaryot Gene Expr. 2014;24(4):281-6
pubmed: 25403959
Indian J Surg. 2015 Apr;77(2):141-6
pubmed: 26139969
Eur J Trauma Emerg Surg. 2014 Oct;40(5):535-9
pubmed: 26814508
Eur Radiol. 2016 Nov;26(11):3874-3887
pubmed: 26945762
Am Health Drug Benefits. 2016 Feb;9(1):23-32
pubmed: 27066193
Mol Imaging Biol. 2016 Oct;18(5):651-8
pubmed: 27074840
Breast Cancer Res. 2016 May 10;18(1):47
pubmed: 27160733
Hypoxia (Auckl). 2015 Dec 11;3:83-92
pubmed: 27774485
J Ultrasound Med. 2017 Dec;36(12):2459-2466
pubmed: 28646597
Clin Cancer Res. 2017 Nov 15;23(22):6912-6922
pubmed: 28899968
Radiology. 2018 Aug;288(2):355-365
pubmed: 29664342